Samantha Prout - 03 Sep 2021 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
Principal Accounting Officer
Signature
/s/ Christian Formica, Attorney-in-Fact
Issuer symbol
FOLD
Transactions as of
03 Sep 2021
Net transactions value
-$11,165
Form type
4
Filing time
08 Sep 2021, 18:42:53 UTC
Previous filing
25 Aug 2021
Next filing
14 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FOLD Common Stock Options Exercise $19,879 +1,980 +2.4% $10.04 85,150 03 Sep 2021 Direct
transaction FOLD Common Stock Options Exercise $28,125 +2,945 +3.5% $9.55 88,095 03 Sep 2021 Direct
transaction FOLD Common Stock Sale $59,168 -4,925 -5.6% $12.01 83,170 03 Sep 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FOLD Stock Options (right to buy) Options Exercise $0 -1,980 -38% $0.000000 3,168 03 Sep 2021 Common Stock 1,980 $10.04 Direct F3
transaction FOLD Stock Options (right to buy) Options Exercise $0 -2,945 -19% $0.000000 12,182 03 Sep 2021 Common Stock 2,945 $9.55 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.00 to $12.0650 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 As of September 3, 2021, 1,980 options were fully vested and exercisable and 3,168 remained unvested from this grant.
F4 As of September 3, 2021, 6,301 options were fully vested and exercisable and 8,826 remained unvested from this grant.